Monday, 8 March 2021

Gut microbiome manipulation could result from virus discovery



Scientists have discovered how a common virus in the human gut infects and takes over bacterial cells -- a finding that could be used to control the composition of the gut microbiome, which is important for human health.

"CrAssphages are the most abundant viruses infecting bacteria in the human gut. As such, they likely control our intestinal community of microbes (the microbiome)," said co-author Konstantin Severinov, a principal investigator at the Waksman Institute of Microbiology and a professor of molecular biology and biochemistry in the School of Arts and Sciences at Rutgers University-New Brunswick. "Understanding how these tiny viruses infect bacteria may allow scientists to control and manipulate the makeup of the microbiome, either by increasing the proportion of beneficial bacteria in our intestines or decreasing the number of harmful bacteria, thus promoting health and fighting disease."

Scientists found that crAssphages use their own enzyme (an RNA polymerase) to make RNA copies of their genes. RNA has the genetic information to make proteins. All cells, ranging from bacterial to human, use such enzymes to make RNA copies of their genes. And these enzymes are very similar in all living matter, implying that they're ancient and related by common ancestry, Severinov said.

When the team revealed the atomic structure of a crAssphage enzyme, they were surprised to learn that it is distinct from other RNA polymerases but closely resembles an enzyme in humans and other higher organisms that is involved in RNA interference. Such interference silences the function of some genes and may lead to certain diseases.

"This is a startling result. It suggests that enzymes of RNA interference, a process that was thought to occur only in cells of higher organisms, were 'borrowed' from an ancestral bacterial virus early in evolution," Severinov said. "The result provides a glimpse of how cells of higher organisms evolved by mixing and matching components of simpler cells and even their viruses."

"In addition to deep evolutionary insights, phage (viral) enzymes such as crAssphage RNA polymerase may be used in synthetic biology to generate genetic circuits that do not exist in nature," he said.

Synthetic biology involves redesigning organisms so they can, for example, produce a medicine, nutrient or fuel, sense something in the environment or clean up pollutants, according to the National Human Genome Research Institute.

"We are now trying to match the thousands of different crAssphage viruses in our gut with the bacterial hosts they infect," Severinov said. "By using just the 'right' bacterial virus, we will be able to get rid of bacteria it infects, which will allow us to alter the composition of the gut microbiome in a targeted way."

Leonid Minakhin at the Waksman Institute of Microbiology contributed to the study along with scientists at many other institutions.


Journal Reference:

  1. Arina V. Drobysheva, Sofia A. Panafidina, Matvei V. Kolesnik, Evgeny I. Klimuk, Leonid Minakhin, Maria V. Yakunina, Sergei Borukhov, Emelie Nilsson, Karin Holmfeldt, Natalya Yutin, Kira S. Makarova, Eugene V. Koonin, Konstantin V. Severinov, Petr G. Leiman, Maria L. Sokolova. Structure and function of virion RNA polymerase of a crAss-like phage. Nature, 2020; DOI: 10.1038/s41586-020-2921-5
Posted by Dr. Tim Sandle, Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)

Cannabis For Medical And Pharmaceutical Purposes – Part 2: Analytical Quality Control

 



As the use of medicinal cannabis becomes more widespread (and in parallel, recreational cannabis),together with several examples of cannabis-based pharmaceutical products in development, the quality aspects (safety and efficacy) that would apply to any healthcare or pharmaceutical product need to be rigorously applied.

This article, which follows on from an introductory article about medicinal and pharmaceutical cannabis, provides an overall assessment of pharmaceutical and medicinal cannabis and the quality aspects, focusing on analytical methods and outcomes. There are various analytical tests that might be required to test the quality of the cannabis product.  These include tests for potency, moisture content, residual solvents, contaminants (heavy metals and pesticides). Most methods are based on chromatography equipment, in order to separate, identify and quantify each component, or cannabinoid at low levels (parts/million).

 

The article also refers to some recent advances with production processes, designed to bring production to scale, together with other aspects of commercialization like modes of drug delivery, such as inhaled, ingested, absorbed-transdermal and mucosal or injected.   A follow-up article looks at a different type of risk, in the form of the microbiological quality aspects.

See:

Sandle, T. (2020) Cannabis For Medical And Pharmaceutical Purposes – Part 2: Analytical Quality Control, Journal of GxP Compliance, 24 (6): https://www.ivtnetwork.com/article/cannabis-medical-and-pharmaceutical-purposes-%E2%80%93-part-2-analytical-quality-control

 

Posted by Dr. Tim Sandle, Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)

Thursday, 4 March 2021

Free webinar on rapid microbiological water testing


Join us for this webinar where you will learn about how the Milliflex® Quantum system operates and get insights about a practical case of validation on water samples with Tim Sandle, Ph.D., Head of Microbiology, at Bio Products Laboratory Limited. 

 

Click here to register

  

Posted by Dr. Tim Sandle, Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)

Wednesday, 3 March 2021

Important cGMP Considerations For Implementing Electronic Batch Records



While human error is never the ultimate root cause, mistakes in batch records can have considerable consequences for the release of medicines in terms of delays and rejections. In more serious cases, when the error is initially undetected, the consequence can be a product recall. Errors can be minimized through the implementation of electronic batch records. However, with any electronic system within the pharmaceutical industry, the requirements of current good manufacturing practice (cGMP), including those of data integrity, need to be met. These essential requirements need to be included in the initial design phase of the system.

In relation to this topic, Tim Sandle has written a new article for Pharmaceutical Online, titled "Important cGMP Considerations For Implementing Electronic Batch Records"

The article can be found here: Electronic Batch Records

Posted by Dr. Tim Sandle, Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)

Tuesday, 2 March 2021

Cleanroom Contamination Prevention & Control: A Practical Guide to the Science



A new cleanroom contamination control and microbiology book from PDA / DHI books, edited by Ziva Abraham and Morgan Pollen, has been issued. I have contributed two chapters. One is on cleanroom commissioning, and the other is jointly written with my Pharmig colleagues Racjel Kirkham, Laura Guardi and Kim Moorwood,and it is about the validation of disinfectants.

Cleanroom Contamination Prevention & Control: A Practical Guide to the Science by Tim Sandle on Scribd

 My chapters are:

Sandle, T. (2021) Designing, commissioning and risk assessing cleanrooms for biocontamination control. In Abraham, Z. and Polen, M. (Eds.) Cleanroom Contamination Prevention & Control: A Practical Guide to the Science, DHI/PDA, River Grove, IL, USA, pp219-285. ISBN Number: 9781942911548

Sandle, T., Gaurdi, L., Kirkham, R. and Moorwood, K.(2021) Validation of disinfectants. In Abraham, Z. and Polen, M. (Eds.) Cleanroom Contamination Prevention & Control: A Practical Guide to the Science, DHI/PDA, River Grove, IL, USA, pp383-416. ISBN Number: 9781942911548

 


Posted by Dr. Tim Sandle, Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)

Monday, 1 March 2021

Vaccine development and distribution



 

World Health Organization (WHO) says better health for everyone, everywhere. It is responsible for international public health. With the Current pandemic, WHO is ensuring good health for all. Various treatments and therapeutics for COVID-19 are evaluated rigorously and given a green flag for use with terms and conditions as necessary. 

A guest post by Aparna Rane

This article is focused on Vaccines as given in series by WHO. It is explained in six parts on vaccine development and distribution.

1) PART ONE: How do vaccines work?

2) PART TWO: How are vaccines developed?

3) PART THREE: Manufacturing, safety, and quality control of vaccines

4) PART FOUR: The different types of COVID-19 vaccines

5) PART FIVE: Access and allocation: how will there be fair and equitable allocation of limited supplies?

6) PART SIX: Country readiness for COVID-19 vaccines

1) PART ONE How do vaccines work?

The Human body has many systems for its protection. The protection can be from disease causing organisms, physical harm, or mental harm. The system that plays important role in protecting us from causing us any disease is the immune system. Pathogens are disease causing organisms which when enter our body, stimulates to produce antibodies to protect us. This antigen-antibody complex destroys the pathogen and stops the disease. While doing this it also produces memory cells. So in the future, when the body is exposed to the pathogen, the antibodies are formed again to protect the body.

Vaccines use this organism in various forms, but without disease causing ability of it and produces antibodies in the body. So in future, if the body encounters the real pathogen, the body will be ready to eradicate the disease with the help of the immune system.

Herd immunity helps the people who are unable to be vaccinated. The Link for the details is here

2) PART TWO: How are vaccines developed?

Vaccines developed are required to be safe. It contains antigen, preservatives, stabilizers, surfactant, Residual, diluent, adjuvant.

Each vaccine undergoes screening and evaluation. It has a preclinical and clinical trial stage. Preclinical stage in animals to evaluate the safety and potential to prevent disease. Clinical Trial stages in human with three phases

Phase I: small number and safety and immune response generation.

Phase II: several hundred volunteers to further assess its safety and ability to generate an immune response.

Phase III: thousands of volunteers – and compared to a similar group of people who didn’t get the vaccine.

After receiving results, regulatory bodies in each country closely review the study data and decide whether to authorize the vaccine for use. Post-approval continuous monitoring of vaccine safety and effectiveness is done. The Link for the details is here

3) PART THREE: Manufacturing, safety, and quality control of vaccines

After successful clinical trials, the production of vaccines is undergone in a very strict way. The quality, safety, and efficacy criteria are essential elements of a vaccine. Every country has its own regulatory requirements and standards set for it like WHO has Prequalification (PQ)assessment process. Also during a Global pandemic situation like the ongoing COVID-19 pandemic, the WHO Emergency Use Listing Procedure (EUL) may be used to allow emergency use of the vaccine. Also, various other procedures like USFDA EUA (Emergency Use Authorization) for vaccines are done as per the situation requirements.

Once the vaccine is produced, it is quality checked and bottled in glass vials, as they are durable and maintain integrity. They are stored as per the requirement and transported globally with utmost care. The Link for the details is here

4) PART FOUR: The different types of COVID-19 vaccines


Various companies are involved in different types of vaccine manufacturing. Many vaccines to date have received Emergency Use approval based on their clinical trial data study. These vaccines are continuously monitored for safety and efficacy since corona variants are also emerging with time.

The different types of vaccines are

a) they use a whole virus or bacterium;

b) just the parts of the germ that triggers the immune system;

c) just the genetic material that provides the instructions for making specific proteins and not the whole virus.

a) Whole virus

Here three approaches can be used

a.1) Inactivated vaccine

The virus is inactivated or killed by chemical, heat, or radiation. It requires special lab conditions for production and has a long production time. It likely requires more than one dose.

a.2) Live attenuated vaccine

The virus is live but disease-causing ability is weakened. It also needs a special lab and is time-consuming. This may not be suitable with compromised immune systems people.

a.3) Viral vector vaccine

A safe virus called as a vector is used along with the pathogen protein. The protein then triggers the required immune response.

b) parts of the germ

Also called as a subunit vaccine. As the name suggests, it contains a subunit or part of the organism. Most childhood vaccines are these types.

C) genetic material

The genetic material DNA or RNA is used in the vaccine. This approach is new for vaccine development. Earlier genetic material vaccines were undergoing clinical trials still, COVID-19 mRNA vaccine is the first to get EUA. The DNA or mRNA is instructed to form the proteins, which are then recognized by the immune system to generate the response. The Link for the details is here

5) PART FIVE: Access and allocation: how will there be fair and equitable allocation of limited supplies?

Once a vaccine is allowed for use, its equal and fair distribution is essential. WHO has formed COVAX (The COVID-19 Vaccines Global Access) Facility. It is formed to bring together nations regardless of economic status to have an equal distribution of vaccines. The vaccine allocation will be done in Phase I and Phase II. Also, humanitarian buffer will be kept for use whenever required. The Link for the details is here

6) PART SIX: Country readiness for COVID-19 vaccines

Every nation should have its distribution plan for vaccine ready, in order to avoid any hassle during vaccination. National Deployment and Vaccination Plans (NDVPs) are reviewed by WHO so that 92 low and middle-income countries under COVAX gets vaccination program done effectively. The Link for the details is here . 


 Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)

Special offers